ApoB & LDL particle reduction
One of 5 mechanistic pathways to 🫀 Heart, cholesterol & blood pressure · 12 options
Atherosclerosis is caused by ApoB-containing particles crossing into the arterial wall and being retained. Fewer particles, less retention — and the relationship is causal, dose-dependent and cumulative over a lifetime, which is why starting early matters more than starting aggressively.
ApoB counts atherogenic particles; LDL-C estimates the cholesterol inside them. When the two disagree — common in insulin resistance — ApoB is right and LDL-C is falsely reassuring.
ApoB (Apolipoprotein B)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)Apolipoprotein A-1Lipoprotein(a) — Lp(a)🫀 Real Cardiovascular Risk covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Rosuvastatin
HMG-CoA reductase inhibition. Reduces ApoB substantially with the best outcome data of any lipid intervention. Muscle symptoms are real, usually dose-related and frequently nocebo in blinded rechallenge — both things can be true.
💉 Ezetimibe
Blocks NPC1L1-mediated intestinal cholesterol absorption. A completely separate mechanism from statins, so the combination is additive and allows a lower statin dose.
🧬 Bergamot
Citrus bergamot polyphenols inhibit HMG-CoA reductase weakly and improve lipid profile in randomised trials. The most credible natural entry here.
🧬 Red Yeast Rice
Contains monacolin K, which is chemically identical to lovastatin. It works because it is a statin — with unregulated dosing and citrinin contamination risk, which makes it a worse version of the drug rather than a natural alternative.
🧬 Plant Sterols & Stanols
Competitively inhibit cholesterol absorption at the intestinal micelle. 2 g daily lowers LDL by around 10%, and it has food-label approval on that basis.
🧬 Psyllium Husk
Binds bile acids so the liver must pull cholesterol from circulation to make more. Meta-analysis confirms LDL reduction.
🧬 Berberine
Upregulates LDL receptor expression through a mechanism entirely separate from statins — and it works in statin-intolerant patients for exactly that reason.
🧬 Niacin (Flush)
Lowers LDL and Lp(a) and raises HDL — and the outcome trials (AIM-HIGH, HPS2-THRIVE) showed no benefit and net harm on top of statins. A textbook case of moving a number without moving the disease.
🧬 Policosanol
Impressive Cuban trial results that no independent group has ever replicated. Worth knowing as a cautionary tale about single-source evidence.
🧬 Tocotrienols
Suppress HMG-CoA reductase by a different mechanism than statins — degradation rather than inhibition.
🧬 Heart & Cholesterol Stack
Bundled approach across absorption, synthesis and bile-acid routes.
🧬 Amla (Indian Gooseberry)
Randomised trials show meaningful lipid improvement, with effect sizes that are surprisingly large for a fruit extract.
The other 4 routes to heart, cholesterol & blood pressure
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
Want the protocols behind these?
Dosing schedules, stacking, cycle timing and Coach Cam's notes live inside the Academy — plus the full interactive Vault.
Join the Academy — $10/mo →← Open this pathway in the interactive Vault
Frequently asked questions
Atherosclerosis is caused by ApoB-containing particles crossing into the arterial wall and being retained. Fewer particles, less retention — and the relationship is causal, dose-dependent and cumulative over a lifetime, which is why starting early matters more than starting aggressively.
12 options are mapped to this pathway in the Vault, including Rosuvastatin, Ezetimibe, Bergamot, Red Yeast Rice. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 11 carry clinical validation and 1 are mechanistic predictions.
ApoB counts atherogenic particles; LDL-C estimates the cholesterol inside them. When the two disagree — common in insulin resistance — ApoB is right and LDL-C is falsely reassuring. The markers worth checking are ApoB (Apolipoprotein B), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), Apolipoprotein A-1, Lipoprotein(a) — Lp(a).
Unproven is not the same as ineffective. Of the 12 options on this pathway, 11 have clinical validation and 1 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.